Spherix Consulting, a Division of ChromaDex - 6430 Rockledge Dr., Suite 503, Bethesda, MD 20817 since Dec 2012
Senior Science Director
Spherix Consulting, Inc. - Bethesda, MD USA since Jan 2010
Senior Science Consultant
Spherix Consulting, Inc. Dec 2008 - Dec 2009
Science Consultant
National Cancer Institute-Frederick, National Institutes of Health Apr 2005 - Dec 2008
Cancer Research Training Award Postdoctoral Fellow
University of Illinois at Chicago 1999 - 2005
Graduate student
Education:
University of Illinois at Chicago 1999 - 2005
PhD, Pharmacognosy
University of Rochester 1997 - 1999
M.S., Chemistry
Worcester Polytechnic Institute 1993 - 1997
B.S., Chemistry
Skills:
Chemistry Science Fda Lifesciences Regulatory Affairs Research Supplements R&D Biochemistry Analytical Chemistry Food Ingredients Assay Development Life Sciences Cell Biology Critical Thinking Food Industry Strategy Program Evaluation Clinical Research Scientific Writing Data Analysis Collaborative Problem Solving Regulatory Submissions Technical Writing Critical Analysis Project Evaluation Natural Products Herbs Pharmacognosy Chemotaxonomy Scientific Editing Literature Reviews Scientific Analysis Grant Reviewing Research and Development
Thomas Joseph Sayers - Boonsboro MD, US Nancy Lynn Booth - Bethesda MD, US Curtis J. Henrich - Rockville MD, US Alan David Brooks - Frederick MD, US Kirk R. Gustafson - Frederick MD, US Karen L. Erickson - North Oxford MA, US
Assignee:
THE UNITED STATES OF AMERICA - 6011 EXECUTIVE SUITE 325 MC 7660 MD
International Classification:
A61K 38/19 A61P 35/00 A61K 39/395
US Classification:
424 851, 514 193, 514 189, 4241741, 514 11
Abstract:
Disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with a death receptor ligand, which method comprises contacting the cancer cells with a death receptor ligand in conjunction with an effective amount of a compound described herein, for example, a cucurbitacin (I) or a withanolide (II). Also disclosed is a method of inducing apoptosis in cancer cells in a mammal, comprising contacting the cancer cells with a compound described herein, for example, a cucurbitacin (I) or a withanolide (II) and also contacting the cancer cells with a death receptor ligand, whereby apoptosis is induced in the cancer cells.